

LIST OF REFERENCES CITED BY APPLICANT <small>(Use several sheets if necessary)</small>	ATTY. DOCKET NO.	APPLICATION NO.
	6750-189-999	10/567,702
	APPLICANT Richard Kim	
U.S. FILING DATE August 21, 2006	ART UNIT 1643	

U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date mm/dd/yy	Name Of Patentee Or Applicant Of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

		Foreign Patent Document Country Code, Number, Kind Code (If Known)	Date mm/dd/yy	Name Of Patentee Or Applicant Of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published)	T
	C48	ANDERSON et al., 2002, "ErbB receptor tyrosine kinase inhibitors as therapeutic agents" <i>Front. Biosci.</i> 7:d1926-d1940	
	C49	CAPPUZZO et al., 2003, "Gefitinib in pretreated non-small-cell lung cancer (NSCLC): Analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC" <i>J. Clin. Oncol.</i> 21:2658-2663	
	C50	CHEN et al. 2000, "Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3" <i>Biochem. Biophys. Res. Comm.</i> 277: 757-763	
	C51	CHRISTENSEN et al., 2001, "High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo" <i>Clin. Cancer Res.</i> 7:4230-4238	
	C52	CLASSEN et al., 2002, "Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy" <i>Tumor Biol.</i> 23:70-75	
	C53	NICHOLSON et al., 1993, "Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity" <i>Eur. J. Cancer</i> 29A:1018-1023	
	C54	PATERSON et al., 1991, "Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer" <i>Cancer Res.</i> 51:556-567	
	C55	XIA et al., 1999, "Combination of EGFR, HER-2/neu and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members" <i>Clin. Cancer Res.</i> 5:4164-4174	

EXAMINER NYI-4136908v1	DATE CONSIDERED
---------------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.